Stockscreener 앱 받기
7.26
2.29%
-0.17
시간 외 거래:
7.26
Mink Therapeutics Inc 주식(INKT)의 최신 뉴스
Where are the Opportunities in (INKT) - news.stocktradersdaily.com
Kalkine: MiNK Therapeutics Sees Gains Amid Positive Earnings Per Share Momentum - Kalkine Media
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting - Eagle-Tribune
MiNK Therapeutics Annual Meeting: How Shareholders Can Join Virtually on June 18 - Stock Titan
MiNK Therapeutics (NASDAQ:INKT) Stock Price Up 0.1% – Here’s Why - Defense World
MiNK Therapeutics receives NIH grant for GvHD therapy - Investing.com India
MiNK Therapeutics, Inc. Awards Prestigious Niaid Grant to Advance Allo-Inkt Cell Therapy for Prevention of Gvhd in Stem Cell Transplant Patients - MarketScreener
INKT Secures Grant for GvHD Cell Therapy Development | INKT Stoc - GuruFocus
MiNK Therapeutics Receives NIAID Grant to Advance Allo-iNKT Cell Therapy for Graft-Versus-Host Disease Treatment - Nasdaq
MiNK Therapeutics Awarded Prestigious NIAID Grant to - GlobeNewswire
NIH Backs Revolutionary Cell Therapy: MiNK's Solution Could Prevent Deadly Transplant Complications - Stock Titan
(INKT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Amer Sports: The New ONON and DECK of Consumer Discretionary? - The Globe and Mail
MiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programs - MSN
HC Wainwright Cuts Earnings Estimates for MiNK Therapeutics - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2025 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Mink Therapeutics’ Earnings Call Highlights Progress and Optimism - TipRanks
Transcript : MiNK Therapeutics, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
MiNK Therapeutics (INKT) Advances in Immune Response Innovation - GuruFocus
MiNK Therapeutics (INKT) Advances in Immune Response Innovation | INKT Stock News - GuruFocus
MiNK Therapeutics Reports Clinical Advancements and Financial Update for Q1 2025, with Focus on iNKT Cell Therapies - Nasdaq
Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress - GlobeNewswire
MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday - Defense World
Refractory Multiple Myeloma Pipeline Appears Robust With 75+ - openPR.com
How to Take Advantage of moves in (INKT) - news.stocktradersdaily.com
MiNK Therapeutics to Announce Q1 2025 Financial Results and Host Conference Call on May 15th - Nasdaq
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewswire
Geode Capital Management LLC Lowers Stock Position in MiNK Therapeutics, Inc. (NASDAQ:INKT) - Defense World
Learn to Evaluate (INKT) using the Charts - news.stocktradersdaily.com
Comparing Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) - Defense World
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - Business Wire
LIfT BioSciences appoints new CSO - Bdaily
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer - EIN News
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire
(INKT) Trading Report - news.stocktradersdaily.com
Reviewing MiNK Therapeutics (NASDAQ:INKT) & Creative Medical Technology (NASDAQ:CELZ) - The AM Reporter
HC Wainwright Issues Negative Forecast for INKT Earnings - Defense World
What is William Blair’s Forecast for INKT Q1 Earnings? - Defense World
What is William Blair’s Estimate for INKT Q1 Earnings? - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics (NASDAQ:INKT) Given Buy Rating at HC Wainwright - Defense World
MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports 2024 Progress and Financials - TipRanks
MiNK Therapeutics’ Earnings Call Highlights Strategic Gains - TipRanks
MiNK Therapeutics, Inc. SEC 10-K Report - TradingView
Earnings call transcript: Mink Therapeutics Q4 2024 reports reduced net loss - Investing.com
Mink Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress - GlobeNewswire
MiNK Therapeutics Reports 2024 Financial Results and Highlights Clinical Advancements in iNKT Cell Therapies - Nasdaq
MiNK Therapeutics reports Q4 EPS (62c), consensus (50c) - TipRanks
Earnings Scheduled For March 18, 2025 - Benzinga
AGENUS INC SEC 10-K Report - TradingView
(INKT) Technical Pivots with Risk Controls - Stock Traders Daily
Mink Therapeutics Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
1.86%
1.98%
자본화:
|
볼륨(24시간):